CagriSema
Last updated
Amylin analog (cagrilintide) plus GLP-1 agonist (semaglutide). Once weekly.
Other GLP-1 medicines at sellers we link to

Lowest compounded tirzepatide on a monthly plan, not FDA-approved
$69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

Lowest compounded semaglutide on a monthly plan, not FDA-approved
$59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before
No seller we link to sells cagrisema; these are different medicines, compounded and not FDA-approved. Those sellers pay us if you buy, which never changes a price we show.
Catalog reviewed Nov 4, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.
Data updated . What changed
Average weight lost in its trials
- 2.4 mg / 2.4 mg weekly (CagriSema)REDEFINE-1 (Phase 3) · 68 wks−22.7% (prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) (-22.7% at 68 wks · REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema))about 45 lb at 200 lb
Averages from separate trials, so they are not a head-to-head ranking and not a prediction. Pounds apply the percentage to a 200 lb starting weight.
Investigational: not FDA-approved for this or any use. It is still being studied in trials.
What to know about CagriSema
An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.
- Mean weight change in the cited trial
- −22.7% (prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) (-22.7% at 68 wks · REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema))
REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema)
- A1c reduction in the cited trial
- −1.9 pp (doi.org/10.1016/S2213-8587(26)00125-7) (-1.91 percentage points at 68 wks (REIMAGINE 2, type 2 diabetes, assuming adherence) · REIMAGINE 2 (Phase 3 T2D) · HbA1c change in percentage points)
REIMAGINE 2 (Phase 3 T2D)
- Stopped treatment for adverse events
- 6% (globenewswire.com/news-release/2025/06/22/3103044/0/en/Novo-Nordisk-A-S-CagriSema-2-4-mg-2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-REDEFINE-1-published-in-New-England-Journal-of-Medicine.html) (6% vs 3.7% placebo · REDEFINE 1 (2.4/2.4 mg, obesity))
REDEFINE 1 (2.4/2.4 mg, obesity)
- FDA shortage report
- In development
Investigational. Not FDA-approved.
- Route & frequency
- Once weekly
Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.
Investigational uses
CagriSema (investigational)
Obesity; type 2 diabetes (investigational)
An investigational fixed combination of the long-acting amylin analog cagrilintide and semaglutide, pairing two complementary satiety pathways.
Dosing, warnings & contraindications
Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.
No approved label (investigational)
CagriSema is investigational. See its registered studies below. Search DailyMed (dailymed.nlm.nih.gov).
Side effects reported in the trial
Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.
Discontinued for side effects
6% (globenewswire.com/news-release/2025/06/22/3103044/0/en/Novo-Nordisk-A-S-CagriSema-2-4-mg-2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-REDEFINE-1-published-in-New-England-Journal-of-Medicine.html) (6% vs 3.7% placebo · REDEFINE 1 (2.4/2.4 mg, obesity))
Reported as 6% vs 3.7% placebo. The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.
Had nausea
55% (globenewswire.com/news-release/2025/06/22/3103044/0/en/Novo-Nordisk-A-S-CagriSema-2-4-mg-2-4-mg-demonstrated-22-7-mean-weight-reduction-in-adults-with-overweight-or-obesity-in-REDEFINE-1-published-in-New-England-Journal-of-Medicine.html) (Nausea in the drug arm · REDEFINE 1 (2.4/2.4 mg, obesity))
The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.
GI events dominated (nausea 55%, constipation 31%, vomiting 26%), mostly transient and mild-to-moderate; despite high nausea, AE discontinuation stayed relatively low.
From REDEFINE 1 (2.4/2.4 mg, obesity). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source (globenewswire.com).
Direct trial comparisons
Read the results for the exact products, doses, and participants studied.
- REDEFINE-4: CagriSema vs tirzepatide
Adults with obesity and at least one associated condition. 84 weeks. Sponsor announcement.
- REIMAGINE 4: CagriSema vs Mounjaro in type 2 diabetes
Adults with type 2 diabetes inadequately controlled with metformin, with or without an SGLT2 inhibitor. 68 weeks. Sponsor announcement.
- REIMAGINE 5: CagriSema 1.0 mg vs Mounjaro 5 mg in type 2 diabetes
Adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor, or both. 60 weeks. Sponsor announcement.
Clinical trials
No indexed trial records available
Registered trials load from ClinicalTrials.gov on schedule. Search ClinicalTrials.gov (clinicaltrials.gov).
Related GLP-1s to compare
FDA's warning letters naming CagriSema
5 letters to companies selling it. Nobody can legally sell CagriSema today.
- PekCura Labs (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/pekcura-labs-721709-03312026)Mar 31, 2026
- Prime Sciences (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/prime-sciences-721805-03312026)Mar 31, 2026
- Darmerica, LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/darmerica-llc-716152-12082025)Dec 8, 2025
- Xcel Research LLC (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024)Dec 10, 2024
- Summit Research Peptides (fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024)Dec 10, 2024
Latest CagriSema trials and reviews
- Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial (pubmed.ncbi.nlm.nih.gov/42009015)
Randomized trial · Lancet Diabetes Endocrinol · Apr 17, 2026 · Yamauchi T et al. · cited by 1
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (pubmed.ncbi.nlm.nih.gov/40544433)
Randomized trial · N Engl J Med · Jun 22, 2025 · Garvey WT et al. · cited by 168
Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.